A lab-grown brain is the most complete ever developed, equivalent to the brain maturity of a five-week-old foetus.
Cancer requires extensive and fast division in order to become a serious threat, but this feature also renders it vulnerable, allowing certain growth pathways to be targeted. A new drug candidate has emerged which exploits this weakness, overstimulating proteins required for growth — tipping cellular stress in virulent cancer cells over the edge.
“No prior drug has been previously developed or proposed that actually stimulates an oncogene to promote therapy. Our prototype drug works in multiple types of cancers and encourages us that this could be a more general addition to the cancer drug arsenal.”
Many types of cancer require specific mutations in genes related to growth, and one particular target is the steroid receptor coactivator (SRC) family of oncogenes. These lie at the centre of signalling pathways used to grow rapidly, and conventional research has focused on inhibiting them to prevent tumour growth. Instead of inhibiting, this new strategy aims to upregulate their activity, overstimulating them to an extent that destroys the host cell. In their search for a suitable molecule which might cause such stimulation, researchers stumbled across a compound labeled MCB-613.
Lifespan.io is running a SENS fundraiser to aid research into Mitochondrial repair. This is a new fundraiser platform to help get important regenerative medicine research funded and underway. Let us hope this is the start of how research could be funded and that it opens up faster progress.
Engineering backup copies of mitochondrial genes to place in the nucleus of the cell, aiming to prevent age-related damage and restore lost mitochondrial function.
EchoPixel uses virtual reality to help doctors visualize each patient’s unique anatomy and internal structure in a floating 3D image.
Meanwhile there is something important going on in the fight against baldness.
As in the majority of tissues, the hair follicle has stem cells. There are two types of stem cells that are responsible for the continuous renewal of the follicles. The first type is called active stem cells and they start dividing quite easily. Stem cells of the second type are called quiescent and in case of the new hair growth they don’t start dividing as easily. At the same time, the new hair is based primarily on quiescent cells, which attracted close attention of researchers to these cells. At first people thought that baldness was due to this type of cells.
However, recent studies showed that bald men did have those quiescent cells in their follicles. The problem was that they didn’t divide at all and didn’t contribute to forming new hairs.
An interesting little Bioviva clip about their upcoming gene therapy work.
CEO Liz Parrish discusses BioViva and gene therapy…. Diseases of aging beware.
Registered Clinical Trials Make Positive Findings Vanish
By having to state their methods and measurements before starting their trial, researchers cannot then cherry-pick data to find an effect once the study is over. This maybe one of the biggest causes for the decline in positive effects from treatments
A study showing a fall in positive trial results after the roll-out of clinicaltrials.gov attracted much attention on social media.
Everything makes you fat! Gluten-free food is the key to eternal youth! You need to poop once per day or you’ll die! You’ll find tons of equally ridiculous health claims around the internet, and some of them are widely believed. Today we’re taking a look at 10 common myths and uncovering the truth.
While we’ve learned a lot about health issues here at Lifehacker over the years, we can’t claim expertise on any particular subject. To help us get to the root of these myths, we solicited the help of three experts: Dr Carly Stewart (medical expert at Money Crashers), Andy Bellatti (Las Vegas-based registered dietitian), and Dr Spencer Nadolsky (medical editor at Examine.com). They all offer a unique perspective on each myth but mostly came to the same conclusions: we have a lot of silly misinformation out there about our health.
Undoubtedly one of the most exciting areas within the 3D printing space is that of bioprinting. Using layer-by-layer fabrication methods, a number of companies are in the process of pushing forward a new paradigm shift within the medical implant, transplantation, and surgical spaces. While the media has mainly focused on Organovo, the company behind the world’s first 3D printable liver tissue, there are actually several other companies involved in this incredible space. Here are 3DPrint.com we thought it would be helpful to underline just a handful of those companies that may be about to change medicine as we know it.
Organovo The company, headquartered in San Diego, California, has been at the forefront of 3D bioprinting research for some time now. Not only are they currently bringing revenues in by providing pharmaceutical companies with their 
exVive3D™ Liver Tissue for drug toxicity testing, but they have partnered with major companies in the health space including L’Oréal and Merck, and are planning on introducing their exVive3D™ Kidney Tissue product by next year. With an ultimate goal of 3D printing patches made of human tissue for failing organs, and eventually entire organs for transplantation, Organovo certainly has their work cut out for them.
